nach oben

Familial Cancer

Erschienen in:

01.08.2016 | Original Article

Community attitudes towards a Jewish community BRCA1/2 testing program

verfasst von: Nicole Cousens, Rajneesh Kaur, Bettina Meiser, Lesley Andrews

Erschienen in: Familial Cancer | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

About 2.5 % of the Ashkenazi-Jewish population carry one of three “founder” mutations in BRCA1 and BRCA2 (BRCA1/2). Currently, testing is offered to Jewish people with a personal and/or family history of breast and/or ovarian cancer; however less than half of BRCA1/2 carriers within the Jewish population are aware of their family history. Population-based testing in other countries has shown to greatly increase the number of mutation carriers identified, compared to targeted testing of people with a family history. We aimed to assess the Australian Jewish community’s attitudes towards such a program, including acceptability and interest in having education and testing offered online. Members of Sydney-based Jewish organisations who self-identified as being Jewish were invited by e-mail to participate in an online survey. Of 370 individuals who completed the survey, 96.8 % supported a Jewish community-based BRCA1/2 testing program, and 65.6 % reported being personally interested in undergoing the test. Younger adults aged below 50 years were more interested in undergoing the test than those aged 50 years and above. Almost half (42.9 %) were aware of a family member with breast and/or ovarian cancer; however, of these, 77.1 % had not yet undergone testing. Sixty-five (65.1 %) percent were satisfied with providing consent online, while only 39.6 % of participants’ first preference for method of information provision was online. Given the high level of support, and interest in a community testing program, the development and evaluation of a cost-effective and interactive, online BRCA1/2 community testing program appears warranted.

Nur mit Berechtigung zugänglich

Alsop K, Fereday S, Meldrum C, deFazio A, Emmanuel C, George J, Dobrovic A, Birrer MJ, Webb PM, Stewart C, Friedlander M, Fox S, Bowtell D, Mitchell G (2012) BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663. doi:10.1200/jco.2011.39.8545 CrossRefPubMedPubMedCentral

Campeau PM, Foulkes WD, Tischkowitz MD (2008) Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet 124(1):31–42. doi:10.1007/s00439-008-0529-1 CrossRefPubMed

Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, Ozcelik H, Goss P, Allingham-Hawkins D, Hamel N, Di Prospero L, Contiga V, Serruya C, Klein M, Moslehi R, Honeyford J, Liede A, Glendon G, Brunet JS, Narod S (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247CrossRefPubMed

Moslehi R, Chu W, Karlan B, Fishman D, Risch H, Fields A, Smotkin D, Ben-David Y, Rosenblatt J, Russo D, Schwartz P, Tung N, Warner E, Rosen B, Friedman J, Brunet JS, Narod SA (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66(4):1259–1272. doi:10.1086/302853 CrossRefPubMedPubMedCentral

Bahar AY, Taylor PJ, Andrews L, Proos A, Burnett L, Tucker K, Friedlander M, Buckley MF (2001) The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer 92(2):440–445CrossRefPubMed

Struewing JP, Abeliovich D, Peretz T, Avishai N, Kaback MM, Collins FS, Brody LC (1995) The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet 11(2):198–200. doi:10.1038/ng1095-198 CrossRefPubMed

Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA (1999) The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet 64(4):963–970CrossRefPubMedPubMedCentral

Roa BB, Boyd AA, Volcik K, Richards CS (1996) Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet 14(2):185–187. doi:10.1038/ng1096-185 CrossRefPubMed

Rosenthal E, Moyes K, Arnell C, Evans B, Wenstrup RJ (2015) Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry. Breast Cancer Res Treat 149(1):223–227. doi:10.1007/s10549-014-3218-x CrossRefPubMed

10.

Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, Garber JE, Neuhausen SL, Matloff E, Eeles R, Pichert G, Vant’ veer L, Tung N, Weitzel JN, Couch FJ, Rubinstein WS, Ganz PA, Daly MB, Olopade OI, Tomlinson G, Schildkraut J, Blum JL, Rebbeck TR (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304(9):967–975. doi:10.1001/jama.2010.1237 CrossRefPubMedPubMedCentral

11.

Kast K, Rhiem K (2015) Familial breast cancer-targeted therapy in secondary and tertiary prevention. Breast Care (Basel, Switzerland) 10(1):27–31. doi:10.1159/000380756 CrossRef

12.

HGSA (2014) Pre-symptomatic and predictive testing for genetic disorders. Human Genetics Society of Australasia, Alexandria

13.

Metcalfe KA, Eisen A, Lerner-Ellis J, Narod SA (2015) Is it time to offer BRCA1 and BRCA2 testing to all Jewish women? Curr Oncol (Toronto, Ont) 22(4):e233–e236. doi:10.3747/co.22.2527 CrossRef

14.

Manchanda R, Loggenberg K, Sanderson S, Burnell M, Wardle J, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, McGuire A, Beller U, Menon U, Jacobs I (2015) Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: a randomized controlled trial. J Natl Cancer Inst 107(1):379. doi:10.1093/jnci/dju379 CrossRefPubMed

15.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I (2015) Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J Natl Cancer Inst 107(1):380. doi:10.1093/jnci/dju380 CrossRefPubMed

16.

Metcalfe KA, Mian N, Enmore M, Poll A, Llacuachaqui M, Nanda S, Sun P, Hughes KS, Narod SA (2012) Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening. Breast Cancer Res Treat 133(2):735–740. doi:10.1007/s10549-011-1941-0 CrossRefPubMed

17.

Metcalfe KA, Poll A, Llacuachaqui M, Nanda S, Tulman A, Mian N, Sun P, Narod SA (2010) Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2. Clin Genet 78(5):411–417. doi:10.1111/j.1399-0004.2010.01499.x CrossRefPubMed

18.

Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, Narod SA (2010) Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol 28(3):387–391. doi:10.1200/jco.2009.25.0712 CrossRefPubMed

19.

King MC, Levy-Lahad E, Lahad A (2014) Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312(11):1091–1092. doi:10.1001/jama.2014.12483 CrossRefPubMed

20.

Levy-Lahad E, Lahad A, King MC (2015) Precision medicine meets public health: population screening for BRCA1 and BRCA2. J Natl Cancer Inst 107(1):420. doi:10.1093/jnci/dju420 CrossRefPubMed

21.

Gabai-Kapara E, Lahad A, Kaufman B, Friedman E, Segev S, Renbaum P, Beeri R, Gal M, Grinshpun-Cohen J, Djemal K, Mandell JB, Lee MK, Beller U, Catane R, King MC, Levy-Lahad E (2014) Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci USA 111(39):14205–14210. doi:10.1073/pnas.1415979111 CrossRefPubMedPubMedCentral

22.

Levy-Lahad E (2009) Population-based BRCA1/BRCA2 screening in Ashkenazi Jews: a call for evidence. Genet Med 11(9):620–621. doi:10.1097/GIM.0b013e3181b765d3 CrossRefPubMed

23.

Metcalfe KA, Poll A, Royer R, Nanda S, Llacuachaqui M, Sun P, Narod SA (2013) A comparison of the detection of BRCA mutation carriers through the provision of Jewish population-based genetic testing compared with clinic-based genetic testing. Br J Cancer 109(3):777–779. doi:10.1038/bjc.2013.309 CrossRefPubMedPubMedCentral

24.

Barlow-Stewart K, Burnett L, Proos A, Howell V, Huq F, Lazarus R, Aizenberg H (2003) A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students. J Med Genet 40(4):e45. doi:10.1136/jmg.40.4.e45 CrossRefPubMedPubMedCentral

25.

Gason AA, Sheffield E, Bankier A, Aitken MA, Metcalfe SA, Barlow-Stewart K, Delatycki MB (2003) Evaluation of a Tay-Sachs Disease screening program. Clin Genet 63:386–392CrossRefPubMed

26.

Lew RM, Proos AL, Burnett L, Delatycki M, Bankier A, Fietz MJ (2012) Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews. Med J Aust 197(11):652–654CrossRefPubMed

27.

Burnett L, Proos AL, Chesher D, Howell VM, Longo L, Tedeschi V, Yang VA, Siafakas N, Turner G (1995) The Tay-Sachs disease prevention program in Australia: Sydney pilot study. Med J Aust 163(6):298–300PubMed

28.

Albada A, van Dulmen S, Ausems MGEM, Bensing JM (2012) A pre-visit website with question prompt sheet for counselees facilitates communication in the first consultation for breast cancer genetic counseling: findings from a randomized controlled trial. Genet Med 14(5):535–542. http://www.nature.com/gim/journal/v14/n5/suppinfo/gim201142s1.html

29.

Green MJ, Peterson SK, Baker MW, Friedman LC, Harper GR, Rubinstein WS, Peters JA, Mauger DT (2005) Use of an educational computer program before genetic counseling for breast cancer susceptibility: effects on duration and content of counseling sessions. Genet Med 7(4):221–229CrossRefPubMedPubMedCentral

30.

Corp I (2013) IBM SPSS statistics for windows, vol Version 22.0. IBM Corp, Armonk

31.

Lehmann LS, Weeks JC, Klar N, Garber JE (2002) A population-based study of Ashkenazi Jewish women’s attitudes toward genetic discrimination and BRCA1/2 testing. Genet Med 4(5):346–352CrossRefPubMed

32.

Green MJ, McInerney AM, Biesecker BB, Fost N (2001) Education about genetic testing for breast cancer susceptibility: patient preferences for a computer program or genetic counselor. Am J Med Genet 103(1):24–31CrossRefPubMed

33.

Green MJ, Biesecker BB, McInerney AM, Mauger D, Fost N (2001) An interactive computer program can effectively educate patients about genetic testing for breast cancer susceptibility. Am J Med Genet 103(1):16–23CrossRefPubMed

34.

Graham D (2014) The Jewish population of New South Wales: Key findings from the 2011 Census. Monash University, Australian Centre for Jewish Civilisation, Melbourne

35.

Jewish congregations in Sydney. (2009). http://www.nswjbd.org/Jewish-Congregrations-Sydney/default.aspx

Titel: Community attitudes towards a Jewish community BRCA1/2 testing program
verfasst von: Nicole Cousens
Rajneesh Kaur
Bettina Meiser
Lesley Andrews
Publikationsdatum: 01.08.2016
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 1/2017
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-016-9918-0

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Community attitudes towards a Jewish community BRCA1/2 testing program

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2017

Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer

Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort

Exploring clinicians’ attitudes about using aspirin for risk reduction in people with Lynch Syndrome with no personal diagnosis of colorectal cancer

A novel germline POLE mutation causes an early onset cancer prone syndrome mimicking constitutional mismatch repair deficiency

Hereditary leiomyomatosis and renal cell cancer syndrome: identification and clinical characterization of a novel mutation in the FH gene in a Colombian family

Hereditary breast and ovarian cancer: successful systematic implementation of a group approach to genetic counselling

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie